Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Savolitinib completes enrolment for Phase II clinical trial in Papillary Renal Cell Carcinoma
Savolitinib completes enrolment for Phase II clinical trial in Papillary Renal Cell Carcinoma
Shanghai.
Zafgen Issues Statement: Patient Died During Beloranib Trial
Zafgen Issues Statement: Patient Died During Beloranib Trial
BOSTON, Oct.
Valeant under US federal investigation over drug pricing
Valeant under US federal investigation over drug pricing
Canadian pharmaceutical group Valeant says it has received subpoenas from US federal prosecutors seeking information about the pricing and distribution of its drugs, along with how it makes them more ...
J&J says it has plenty of firepower for M&A, buyback or no buyback
J&J says it has plenty of firepower for M&A, buyback or no buyback
Johnson & Johnson ($JNJ) may be embarking on a $10 billion share repurchase program, but that doesn't mean it doesn't have room to make deals.
Danish malaria vaccine discovery provides potential cancer cure
Danish malaria vaccine discovery provides potential cancer cure
COPENHAGEN, Oct.
Former Merck Analyst Gets Three Years for Insider Trading
Former Merck Analyst Gets Three Years for Insider Trading
A former Merck & Co.
aTyr Pharma Initiates Phase 1b/2 Clinical Trial for Patients with Limb Girdle Muscular Dystrophy 2B
aTyr Pharma Initiates Phase 1b/2 Clinical Trial for Patients with Limb Girdle Muscular Dystrophy 2B
SAN DIEGO, Oct.
Lilly pulls the plug on a would-be blockbuster in its latest pipeline peril
Lilly pulls the plug on a would-be blockbuster in its latest pipeline peril
Eli Lilly ($LLY) is shutting down a massive, costly clinical trial after its lead drug came up short in cardiovascular disease, dealing a major blow to the company's pipeline.
These Big Pharma Companies Are in Need of an Acquisition
These Big Pharma Companies Are in Need of an Acquisition
The patent cliff crushed these Big Pharma companies, and now their only opportunity for sustainable growth might be to go shopping for a rival.
Merck promotes Oschmann as CEO to replace Kley
Merck promotes Oschmann as CEO to replace Kley
Merck promoted Stefan Oschmann to be its new chief executive as the German drugmaker looks to revitalise its business by betting on a new generation of cancer treatments.
BMS' Opdivo gets a jump on Keytruda with another early FDA approval
BMS' Opdivo gets a jump on Keytruda with another early FDA approval
Ready for the lung cancer showdown between Merck & Co.
Can GSK's volume strategy offset generic attack on blockbuster Avodart?
Can GSK's volume strategy offset generic attack on blockbuster Avodart?
GlaxoSmithKline ($GSK) has one less tool for propping up its top line.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand